Suzanne Elvidge

Biography for Suzanne Elvidge

Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at selvidge@fiercemarkets.com. Follow @suzannewriter on Twitter.

Articles by Suzanne Elvidge

AstraZeneca's FluMist Quadrivalent to hit U.S. market

The FDA has approved AstraZeneca's ($AZN) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two...

GlaxoSmithKline funds Canadian flu vaccine studies

GlaxoSmithKline ($GSK) is supporting Canadian flu studies to the tune of $12 million. The money will go toward an additional three years of tracking the incidence and severity of flu across Canada in...

UPDATED: Vaccines mean that India celebrates its first year free of polio

Through a huge and coordinated vaccination campaign that included vaccinators going house to house and visiting even the most remote populations, India has just celebrated its first ever year of...

Combined vaccine has low seizure risk in babies

Fever-related seizures (febrile seizures) are pretty scary, and roughly one in 25 children will have one (or more) during their childhood, according to the NIH. Some studies have suggested that some...

World's first kala azar vaccine enters the clinic

Leishmaniasis comes in a number of forms, but visceral leishmaniasis is the worst. Left untreated, it is almost always fatal within two years. However, a Seattle-based nonprofit has started a human...

Universal flu vaccine in first trial in the elderly, boosts responses

For some people, the flu can just be an inconvenience--feeling rotten and perhaps a week off work. However, for elderly people, it can lead to hospitalization, long-term complications and, in some...

Prostate cancer vaccine teams up with antibody

Sometimes, the sum of the parts is greater than the whole, and this can be true for cancer therapies as well. Researchers are hoping that combining Prostvac, the investigational therapeutic cancer...

Nimenrix meningitis vaccine edges closer to the market for GSK

The European Medicines Agency has recommended approval for GlaxoSmithKline's ($GSK) conjugate vaccine against meningococcal disease in adults and children from the age of 12 months. The active...

Norovirus gets it in the nose

Call it what you like--stomach flu, gastroenteritis, tummy bug, winter vomiting virus--norovirus infections are not fun, especially on a cruise ship, and are even worse in a hospital ward. In the...

FDA says no to Novartis' Menveo vax for babies

Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to